Exposure in Leverage Ratio Report PT Bank Mandiri (Persero) Tbk. (Bank Only)

As of June 30, 2021

	(In Millions of			
No	Item	Total		
1	Total consolidated assets as per published financial statements	1.299.225.302		
2	Adjustment for investments in banking, financial, insurance or commercial entities that are consolidated for accounting purposes but outside the scope of regulatory consolidation	(1.487.109)		
3	Adjustment for securitised exposures that meet the operational requirements for the recognition of risk transference	_		
4	Adjustment for temporary exemption of central bank reserves (if applicable)	N/A		
5	Adjustment for fiduciary assets recognised on the balance sheet pursuant to the operative accounting framework but excluded from the leverage ratio exposure measure	N/A		
6	Adjustments for regular-way purchases and sales of financial assets subject to trade date accounting	-		
7	Adjustments for eligible cash pooling transactions	-		
8	Adjustments for derivative financial instruments	4.449.383		
9	Adjustment for securities financing transactions (i.e. repos and similar secured lending)	240.028		
10	Adjustment for off-balance sheet items (i.e. conversion to credit equivalent amounts of off- balance sheet exposures)	93.805.118		
11	Adjustments for prudent valuation adjustments and specific and general provisions which have reduced Tier 1 capital	(82.255.213)		
12	Other adjustments	-		
13	Leverage Ratio Exposure	1.313.977.509		

*) Calcultation Based on POJK No. 31/POJK.03/2019

Leverage Ratio Common Disclosure

PT Bank Mandiri (Persero) Tbk. (Bank Only)

As of June 30, 2021

No.	Item	(In Millions of Rupiah) Period	
	On-Balance Sheet Exposures	Jun-21	Mar-21
1	On Balance Sheet items (excluding derivatives and SFTs, but including collateral)	1.281.154.487	1.277.102.616
2	Gross up for derivatives collateral provided where deducted from the B/S assets pursuant to the operative accounting framework	-	-
3	(Deduction of receivalvels assets for cash variation margin provided in derivatives transaction)	-	
4	(Adjustment for securities received under securities financing transactions that are recognised as an asset)	-	
5	(Specific and general provisions associated with on-balance sheet exposures that are deducted from Basel III Tier 1 Capital)	(62.197.683)	(61.994.648)
6	(Asset amount deducted in determining Basel III Tier 1 Capital and regulatory adjustments)	(21.544.639)	(22.021.637)
7	Total on-balance sheet exposures (excluding derivatives and SFTs) (sum of rows 1 to 6)	1.197.412.165	1.193.086.331
	Derivatives Exposure	Jun-21	Mar-21
8	Replacement cost associated with all derivatives transaction (where applicable net of eligible cash variation margin and/or with bilateral netting)	1.870.134	1.956.031
9	Add on amounts for PFE associated with all derivatives transactions	3.915.059	4.162.165
10	(Exempted central counterparty (CCP) leg of client-cleared trade exposures)	N/A	N/A
11	Adjusted effective notional amount of written credit derivatives	-	-
12	(Adjusted effective notional offsets and add on deductions for written credit derivatives)	-	-
13	Total derivatives Exposures (sum of rows 8 to 12)	5.785.193	6.118.196
	Securities Financing Transaction Exposures	Jun-21	Mar-21
14	Gross SFT assets (with no recognition of netting), after adjusting for sales accounting transaction	16.735.005	36.899.204
15	(Netted amounts of cash payables and cash receivables of gross SFT assets)	-	-
16	CCR exposure for SFT assets	240.028	248.029
17	Agent transaction exposures	-	-
18	Total Securities Financing Transaction Exposures (sum of rows 14 to 17)	16.975.033	37.147.233
	Other Off-Balance Sheet Exposures	Jun-21	Mar-21
19	Off-balance sheet exposure at gross notional amount	316.434.949	295.381.753
20	(Adjustment for conversion to credit equivalent amount)	(219.405.603)	(202.580.110
21	(Specific and general provisions associated with off-balance sheet exposures deducted in determining Tier 1 Capital)	(3.224.228)	(3.583.149
22	Off Balance Sheet Items (sum of rows 19 to 21)	93.805.118	89.218.494
	Capital and Total Exposures	Jun-21	Mar-21
23	Tier 1 Capital	153.535.752	146.397.543
24	Total Exposures (sum of rows 7, 13, 18, 22)	1.313.977.509	1.325.570.254 Mar-21
25	Leverage ratio (including the impact of any applicable temporary exemption of central bank reserves)	11,68%	11,04%
25a	Leverage ratio (excluding the impact of any applicable temporary exemption of central bank reserves)	11,68%	11,04%
26	National Minimum Leverage Ratio Requirement	3,00%	3,00%
27	Applicable Leverage Buffer	N/A	N/A
	Disclosures of mean values	Jun-21	Mar-21
28	Mean value of gross SFT assets, after adjustment for sale accounting transactions and netted of amounts of associated cash payables and cash receivables	14.518.454	59.426.331
29	Quarter-end value of gross SFT assets, after adjustment for sale accounting transactions and netted of amounts of associated cash pavables and cash receivables	16.975.033	37.147.233
30	Total exposures (including the impact of any applicable temporary exemption of central bank reserves) incorporating mean values from row 28 of gross SFT assets (after adjustment for sale accounting transactions and netted of amounts of associated cash payables and cash receivables)	1.311.520.930	1.347.849.352
30a	Total exposures (excluding the impact of any applicable temporary exemption of central bank reserves) incorporating mean values from row 28 of gross SFT assets (after adjustment for sale accounting transactions and netted of amounts of associated cash payables and cash receivables)	1.311.520.930	1.347.849.352
31	Leverage ratio (including the impact of any applicable temporary exemption of central bank reserves) incorporating mean values from row 28 of gross SFT assets (after adjustment for sale accounting transactions and netted of amounts of associated cash payables and cash receivables)	11,71%	10,86%
31a	Leverage ratio (excluding the impact of any applicable temporary exemption of central bank reserves) incorporating mean values from row 28 of gross SFT assets (after adjustment for sale accounting transactions and netted of amounts of associated	11,71%	10,86%

*) Calculation based on POJK No. 31/POJK.03/2019